Literature DB >> 17239662

Differential dysfunction in dendritic cell subsets during chronic HCV infection.

Lynn Averill1, William M Lee, Nitin J Karandikar.   

Abstract

Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease with over 200 million individuals infected worldwide. The vast majority of acutely infected humans develop chronic infection, which is characterized by attenuated antiviral T-cell responses. The mechanisms leading to such attenuation/suppression are poorly understood. It has been proposed that dysfunction of antigen-presenting cells (APC) may underlie the downregulation of antiviral immune responses. However, studies using bulk or in vitro-derived APC populations have resulted in conflicting reports. In this study, we evaluated the functional and immunophenotypic features of ex vivo-purified dendritic cell (DC) subsets during chronic HCV infection. We found that plasmacytoid DC (PDC) from HCV-infected patients (HCV-PDC) showed a striking deficit in IFN-alpha production in response to CpG stimulation. In addition, we found that myeloid DC (MDC) from these patients showed a diminished capacity to induce a mixed lymphocyte response (MLR), correlating with lower levels of HLA-DR and CD86 expression and higher IL-10 production in response to poly-IC stimulation. In contrast, HCV-PDC showed increased ability to stimulate an MLR. Of note, within the HCV-PDC preparation, we noted a distinctly expanded DC subset that expressed some markers of MDC, but showed significantly lower HLA-DR and CD86 expression, suggesting an expansion of DC at an immature/intermediate stage of differentiation. Our studies demonstrate distinct and contrasting dysfunctional features in DC subsets and underscore the importance of evaluating APC subpopulations separately.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17239662      PMCID: PMC1865520          DOI: 10.1016/j.clim.2006.12.001

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  58 in total

Review 1.  DC-SIGN: binding receptor for HCV?

Authors:  Zhi-Hua Feng; Quan-Chu Wang; Qing-He Nie; Zhan-Sheng Jia; Yong-Xin Zhou
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

2.  Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C.

Authors:  Axel Ulsenheimer; J Tilman Gerlach; Norbert H Gruener; Maria-Christina Jung; Carl-Albrecht Schirren; Winfried Schraut; Reinhart Zachoval; Gerd R Pape; Helmut M Diepolder
Journal:  Hepatology       Date:  2003-05       Impact factor: 17.425

3.  Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses.

Authors:  Pablo Sarobe; Juan José Lasarte; Aintzane Zabaleta; Laura Arribillaga; Ainhoa Arina; Ignacio Melero; Francisco Borrás-Cuesta; Jesús Prieto
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

4.  Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8+ T cells.

Authors:  Michaela Lucas; Ana L Vargas-Cuero; Georg M Lauer; Eleanor Barnes; Christian B Willberg; Nasser Semmo; Bruce D Walker; Rodney Phillips; Paul Klenerman
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

5.  Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection.

Authors:  Daniele Accapezzato; Vittorio Francavilla; Marino Paroli; Marco Casciaro; Lucia Valeria Chircu; Agostino Cividini; Sergio Abrignani; Mario U Mondelli; Vincenzo Barnaba
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

6.  Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection.

Authors:  Donald D Anthony; Nicole L Yonkers; Anthony B Post; Robert Asaad; Frederick P Heinzel; Michael M Lederman; Paul V Lehmann; Hernan Valdez
Journal:  J Immunol       Date:  2004-04-15       Impact factor: 5.422

7.  Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection.

Authors:  Heiner Wedemeyer; Xiao-Song He; Michelina Nascimbeni; Anthony R Davis; Harry B Greenberg; Jay H Hoofnagle; T Jake Liang; Harvey Alter; Barbara Rehermann
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

8.  Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection.

Authors:  Nadège Goutagny; Ahmed Fatmi; Victor De Ledinghen; François Penin; Patrice Couzigou; Geneviève Inchauspé; Christine Bain
Journal:  J Infect Dis       Date:  2003-05-29       Impact factor: 5.226

9.  The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection.

Authors:  Eleanor Barnes; Gillian Harcourt; Dave Brown; Michaela Lucas; Rodney Phillips; Geoffrey Dusheiko; Paul Klenerman
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

10.  Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection.

Authors:  Kazushi Sugimoto; Fusao Ikeda; Jason Stadanlick; Frederick A Nunes; Harvey J Alter; Kyong-Mi Chang
Journal:  Hepatology       Date:  2003-12       Impact factor: 17.425

View more
  42 in total

1.  Increased plasmacytoid dendritic cell maturation and natural killer cell activation in HIV-1 exposed, uninfected intravenous drug users.

Authors:  Costin Tomescu; Fuh-Mei Duh; Michael A Lanier; Angela Kapalko; Karam C Mounzer; Maureen P Martin; Mary Carrington; David S Metzger; Luis J Montaner
Journal:  AIDS       Date:  2010-09-10       Impact factor: 4.177

2.  Regulation of host innate immunity by hepatitis C virus: crosstalk between hepatocyte and NK/DC.

Authors:  Sung-Jae Park; Young S Hahn
Journal:  Rev Infect       Date:  2010-07-01

3.  Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

4.  Acute Liver Damage Associated with Innate Immune Activation in a Small Nonhuman Primate Model of Hepacivirus Infection.

Authors:  Cordelia Manickam; Premeela Rajakumar; Lynn Wachtman; Joshua A Kramer; Amanda J Martinot; Valerie Varner; Luis D Giavedoni; R Keith Reeves
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

5.  Viral interactions with B-cells contribute to increased regulatory T-cells during chronic HCV infection.

Authors:  Chris L Ayers; Mihail Firan; Vinodh Pillai; William M Lee; Nitin J Karandikar
Journal:  Viral Immunol       Date:  2011-04       Impact factor: 2.257

Review 6.  Hepatitis C virus and ethanol alter antigen presentation in liver cells.

Authors:  Natalia A Osna
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

7.  Tumor necrosis factor receptor 1 expression is upregulated in dendritic cells in patients with chronic HCV who respond to therapy.

Authors:  Raul Cubillas; Katherine Kintner; Frances Phillips; Nitin J Karandikar; Dwain L Thiele; Geri R Brown
Journal:  Hepat Res Treat       Date:  2010-08-03

8.  Role of A20 in interferon-α-mediated functional restoration of myeloid dendritic cells in patients with chronic hepatitis C.

Authors:  Li Ma; Yun Zhou; Ying Zhang; Yuan Li; Yonghong Guo; Yu He; Jiuping Wang; Jianqi Lian; Chunqiu Hao; Jonathan P Moorman; Zhi Q Yao; Yongxing Zhou; Zhansheng Jia
Journal:  Immunology       Date:  2014-12       Impact factor: 7.397

9.  The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses.

Authors:  Jin-Sung Chung; Makoto Bonkobara; Mizuki Tomihari; Ponciano D Cruz; Kiyoshi Ariizumi
Journal:  Eur J Immunol       Date:  2009-04       Impact factor: 5.532

10.  A class C CpG toll-like receptor 9 agonist successfully induces robust interferon-alpha production by plasmacytoid dendritic cells from patients chronically infected with hepatitis C.

Authors:  N A Libri; S J Barker; W M C Rosenberg; A E Semper
Journal:  J Viral Hepat       Date:  2009-02-24       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.